top of page

FDA gives priority review status to Novartis’ breast cancer drug

Pharma giant Novartis has secured the US Food and Drug Administration (FDA) Priority Review for its advanced breast cancer drug ribociclib (LEE011).

The drug is intended to be used in combination with letrozole as a first-line treatment of postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page